FAQ: Oncotelic's Nanoparticle Technology and Cancer Drug Delivery Breakthrough
Summary
Oncotelic Therapeutics is advancing nanomedicine with its proprietary 20nm Deciparticle™ platform, which enhances cancer drug delivery by achieving full bioavailability and improved tumor targeting compared to conventional oral formulations.
What is the main breakthrough announced in this content?
Oncotelic Therapeutics has begun Phase 1 trials for Sapu003, a 20nm nanoparticle formulation of Everolimus (Afinitor®), achieving full bioavailability and enhanced tumor targeting compared to oral formulations that only provide 10% absorption.
Why is particle size important in cancer drug delivery?
Particle size is critical because it determines how effectively anticancer drugs can reach tumors while minimizing exposure to healthy tissues, with 20nm nanoparticles providing optimal targeting and efficacy compared to conventional delivery methods.
How does Oncotelic’s Deciparticle™ technology improve drug delivery?
The 20nm Deciparticle™ platform achieves full bioavailability through intravenous delivery, maximizing tumor targeting and drug efficacy while overcoming the limitations of oral formulations that typically provide only 10% absorption.
What is Sapu003 and what stage of development is it in?
Sapu003 is a 20nm nanoparticle formulation of Everolimus (Afinitor®) that has received Australian HREC approval and has begun Phase 1 clinical trials for breast cancer treatment.
How is Oncotelic accelerating its drug development pipeline?
Through a strategic partnership with Medicilon, Oncotelic has established a rapid IND platform that supports up to 20 IND projects, shortening development timelines and enabling multiple Deciparticle™ drug candidates to reach clinical testing quickly.
What are the key benefits of this nanoparticle technology compared to traditional cancer treatments?
The technology provides full bioavailability versus 10% with oral formulations, enhanced tumor targeting that minimizes damage to healthy tissues, and reduced side effects compared to conventional chemotherapy.
Where can investors find the latest updates about Oncotelic Therapeutics?
The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC.
What company is developing this nanoparticle technology?
Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing precision nanomedicine with its proprietary Deciparticle™ platform and is currently conducting human trials for its nanoparticle formulations.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 260004